아프리카는 살아있다

권병수,Gwon, Byeong-Su 한국지반공학회 2011 지반 : 한국지반공학회지 Vol.27 No.9

초순수용 막탈기공정 국산화 개발

권병수,백영희,염충균,석진국,이경혁 대한환경공학회 2019 대한환경공학회 학술발표논문집 Vol.2019 No.12

2Stage Cryogenic Submerged Pump의 비교 성능시험에 관한 연구

권병수,장형채,박종환,이기봉 한국가스학회 2018 한국가스학회 학술대회논문집 Vol.2018 No.11

Natural history of non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease

권병수,이준희,고윤석,김우성,송진우,오연목,이상도,이세원,이재승,임채만,최창민,허진원,홍상범,심태선,조경욱 대한결핵 및 호흡기학회 2018 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.126 No.-

Purpose: This study investigated the natural history of non-cavitary nodular bronchiectatic (NC-NB) Mycobacterium avium complex (MAC) lung disease (LD). Methods: Among patients diagnosed with NC-NB MAC-LD between March 2000 and December 2013, 551 patients who were followed until December 2017 were enrolled at a tertiary referral center in South Korea. Patients were subdivided into the progressive and stationary group according to whether treatment was started within 3 years from the time of diagnosis. We also investigated the rate of spontaneous sputum conversion in untreated group. Results: The mean age of 551 patients was 61.1 years. During the median 5.8 years of follow-up, 323 (58.6%) of the patients received treatment within 3 years (progressive group), whereas remaining 228 (41.4%) patients did not (stationary group). Multivariate analysis revealed that age ≤60 years, a positive sputum smear, the presence of any systemic symptoms and Mycobacterium intracellulare isolates were predictors of receiving treatment. Moreover, during the median of 5.0 years follow- up, spontaneous sputum conversion occurred in 52.2% patients among those who did not receive treatment. Conclusions: Among patients with NC-NB MAC-LD, approximately 60% of patients received treatment within 3 years of diagnosis. And about 50% of untreated patients experienced spontaneous sputum conversion.

F-18 Mycobacterium avium complex 폐질환 치료에서 리팜핀과 에탐부톨 약제감수성검사 결과와 치료반응의 관계

권병수,심태선,김미나,성흥섭,정용필,조경욱 대한결핵 및 호흡기학회 2017 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.124 No.0

목적: Mycobacterium avium complex (MAC) 치료에 있어 리팜핀과 에탐부톨의 약제감수성검사(DST)는 치료결과와 관련이 없다고 알려져 있으나 근거는 미약하다. 본 연구는 MAC 폐질환에서 리팜핀과 에탐부톨의 최소억제농도(MIC)가 치료 반응과 관련이 있는지 알아보고자 하였다. 방법: 2000년 3월부터 2013년 12월까지 서울아산병원에서 표준치료를 받은 macrolide 감수성 MAC폐질환 환자 중 리팜핀, 에탐부톨에 대한 DST가 시행된 404명 결과를 분석하였다. DST는 broth microdilution test로 검사하였고, 치료결과는 success와 unfavorable response로 분류하였다. 결과: 404명의 평균 나이는 62세였고, fibrocavitary type이 29%였다. 전체 환자 치료성공률은 69.8%였다. 리팜핀은MIC가 높아짐에 따라 success비율이 낮아지는 경향을 보였고, 특히 MIC 8 μg/ml 이상인 경우 뚜렷하였다. 에탐부톨은 이런 경향이 없었다. 리팜핀, 에탐부톨 MIC가 모두 8 μg/ml 이상인 경우, 둘 다8 μg/ml 미만인 경우에 비해 success비율이 유의하게 낮았다 (58.6% vs 76.0%, p=0.003). 다변량분석에서 리팜핀, 에탐부톨 MIC가 모두 8 μg/ml 이상인 경우가 unfavorable response의 유일한 위험인자였다. (OR 2.17, 95% CI 1.23-3.87, p=0.009). 결론: MAC 폐질환에서 리팜핀과 에탐부톨의 DST결과는 치료반응과 유의한 상관관계가 있는 것으로 보인다.

맞춤형 고순도 공업용수의 재무성 평가를 통한 공급단가 산정에 대한 연구

권병수,이경혁,장암 대한환경공학회 2018 대한환경공학회지 Vol.40 No.11

본 연구는 맞춤형 고순도 공업용수의 생산을 위한 시설의 구축과 운영비용을 포함한 총 비용을 산출하고, 이에 따른 편익을 분석하여 비용과 편익에 따른 재무성 평가를 하는데 목적이 있다. 개략적인 비용을 산출하는 경우 객관적인 자료를 확보하여 적용하는 것은 중요한 요소이다. 전처리공정 및 폐수처리공정에 대해서는 환경부 자료를 인용하여 산출하였으나, 순수 및 초순수 시설에 대한 개략사업비는 전문업체에 견적을 의뢰하여 용량별 사업비를 산출하였다. 반도체 공장을 기준으 로 10,000 m3/d에 대한 할인율 2.21%를 적용하여 재무성 평가를 실시한 결과 편익/비용비 1.03, 순현재가치 6165 백만원, 내 부수익률 3.09%일 경우 공급단가는 3,517 ￦/m3이 산정되었다. 이는 원수를 취수하여 전처리, 순수 및 초순수, 폐수처리시설 에 대한 시설공사비, 운영비를 포함한 공급단가로 현재 고순도 공업용수 사업의 사례와 비교하면 상당한 높은 공급단가이다. 반도체용 고순도 공업용수 사업의 사례들을 확인하여 공정 등에 대해 현실적인 부분들을 고려한다면 공급단가는 2,284 ￦/m3 - 3,517 ￦/m3으로 예상된다. The purpose of this study is to estimate the total cost including the capital operation costs for the production of customized high purity industrial water, and to analyze the benefits and evaluate the financial performance according to the cost and benefits. It is important to obtain and apply objective data when calculating approximate costs. The capital operation costs of pretreatment process and wastewater treatment process were calculated by quoting data from the Ministry of Environment. Rough costs for pure water and ultrapure water facilities were quoted by professional companies and calculated by each project cost. For the benefit/cost ratio=1.03, the net present value=6,165 million won and the internal rate of return=3.09%, the unit price for 10,000 m3/d capacity was estimated at 3,517 ￦/m3. as a result of the financial evaluation with a discount rate of 2.21% based on the ultrapurewater treatment system of semiconductor factory. This is the total price including the pre-treatment and ultra-pure water of facility construction cost and etc. Compared with the current high-purity industrial water business, it is a considerably high total cost. The comparing cases of high purity industrial water for semiconductors, the realistic aspects of the industrial water business process should be considered. The total cost is expected to be ranged from 2,284 ￦/m3 to 3,517 ￦/m3.

Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

권병수,박지현,김우성,송준선,최창민,노진경,이재철 대한결핵및호흡기학회 2017 Tuberculosis and Respiratory Diseases Vol.80 No.2

Background: Third-generation tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR-TKIs) have proved efficacious in treating non-small cell lung cancer (NSCLC) patients with acquired resistance resulting from the T790M mutation. However, since almost 50% patients with the acquired resistance do not harbor the T790M mutation, retreatment with first- or second-generation EGFR-TKIs may be a more viable therapeutic option. Here, we identified positive response predictors to retreatment, in patients who switched to a different EGFR-TKI, following initial treatment failure. Methods: This study retrospectively reviewed the medical records of 42 NSCLC patients with EGFR mutations, whose cancers had progressed following initial treatment with gefitinib or erlotinib, and who had switched to a different firstgeneration EGFR-TKI during subsequent retreatment. To identify high response rate predictors in the changed EGFR-TKI retreatment, we analyzed the relationship between clinical and demographic parameters, and positive clinical outcomes, following retreatment with EGFR-TKI. Results: Overall, 30 (71.4%) patients received gefitinib and 12 (28.6%) patients received erlotinib as their first EGFR-TKI treatment. Following retreatment with a different EGFR-TKI, the overall response and disease control rates were 21.4% and 64.3%, respectively. There was no significant association between their overall responses. The median progressionfree survival (PFS) after retreatment was 2.0 months. However, PFS was significantly longer in patients whose time to progression was ≥10 months following initial EGFR-TKI treatment, who had a mutation of exon 19, or whose treatment interval was <90 days. Conclusion: In patients with acquired resistance to initial EGFR-TKI therapy, switched EGFR-TKI retreatment may be a salvage therapy for individuals possessing positive retreatment response predictors.

Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review

권병수,변정미,이현주,정대훈,이태화,신경화,서동수,김기형 대한암학회 2019 Cancer Research and Treatment Vol.51 No.3

Purpose We investigated the clinical relevance and spectrum of BRCA1/2mutations in Korean ovarian cancer (KoOC) patients. Materials and Methods Two hundred seventy-nine KoOC patients were enrolled from three university hospitals between 2012 and 2017. Their peripheral blood samples were obtained for BRCA1/2 mutation analysis by direct sequencing. Clinicopathological characteristics were retrospectively reviewed, and spectrum analyses of BRCA1/2mutation were assessed by systematic literature review. Results Frequency of BRCA1/2mutations was 16.5% in KoOC patients. BRCA1/2mutations were significantly associated with family history of breast/ovarian cancer (p < 0.001), serous histology (p=0.044), and advanced International Federation of Gynecology and Obstetrics (FIGO) stage (III/IV, p=0.018) but not with early age-of-onset (age < 50, p=0.729). Literature review of BRCA1/2mutations in KoOC patients found 111 (55 distinct) mutations with high proportion of Korean-specific mutations (24/55, 43.6%). Comparing the spectrum of BRCA1/2 mutation between KoOC and Korean breast cancer (KoBC) patients, the ratio of BRCA1-to-BRCA2mutations was different, with BRCA1 (78.4%) being predominant in KoOC and BRCA2 in KoBC (59.2%). The most common mutation also differed between the two (c.3627insA of BRCA1 in KoOC and c.7480C>T of BRCA2 in KoBC). Conclusion The clinical relevance of BRCA1/2 mutations in KoOC patients was confirmed but that of early age-of-onset was not. Possible inconsistency in the ratio of BRCA1-to-BRCA2mutations and the most common mutation between KoOC and KoBC may probably suggest presence of mutation sequence-associated penetrance tendency in hereditary Korean breast and ovarian cancer. These data may provide insights for optimal genetic counseling and prophylactic treatment for at-risk relatives of KoOC patients.

초순수용 막탈기공정 용존산소 제거효율 평가

권병수,백영희,염충균,석진국,이경혁 대한환경공학회 2019 대한환경공학회지 Vol.41 No.10

Objectives : In this study, the efficiency of dissolved oxygen removal was evaluated in the domestic membrane degassing (MDG) process for ultrapure water production. 3M (Liqui-celTM) is mainly used for membrane degassing (MDG) process in ultrapure water. The domestic MDG process is used in CO2 gas processes in petrochemical processes. The water quality of 3M (Liqui-celTM) process managed below 1 μg/L. The efficiency of dissolved oxygen removal for the domestic MDG process was evaluated and compared with that of external films. Methods : 3M (Liqui-celTM) and domestic membrane degassing process were evaluated by ultrapure membrane degassing process. First, the DO removal rate was evaluated for the evaluation of the hollow fiber membranes, but the operating conditions such as vacuum degree and nitrogen gas injection amount were changed. Secondly, the solubility of organics in the module was evaluate. And the efficiency of dissolved oxygen removal according to four operating criteria (inlet DO concentration, vacuum level, nitrogen gas volume, and supply pressure) was evaluated. Results and Discussion : First, the hollow fiber membrane of 3M (Liqui-celTM) is DO 3.8 ~ 4.9 mg/L and the domestic hollow fiber membrane is 3.4 ~ 4.8 mg/L depending on the operating conditions. As a result of evaluation of the hollow fiber membrane, the removal efficiency of the domestic hollow fiber membrane was better. Secondly, As a result of the application of domestic MDG, the dissolved oxygen (DO) concentration of the product is 0 μg/L when the incoming DO concentration is 10 μg/L or less. There was no difference compared to 3M. When the operating conditions such as incoming DO concentration, vacuum level, nitrogen gas and supply pressure were changed, the DO removal rate was lowered to 61 ~ 65%. Conclusions : In the evaluation of the MDG hollow fiber membrane, the removal efficiency of the domestic membrane was better. However, evaluating the module lowers the efficiency. The packing efficiency of the module is low and the resistance of the membrane is increased, resulting in low removal efficiency. Improvement of domestic MDG membrane should reduce the pore size of membrane and reduce the thickness of membrane. As a result, the dissolved oxygen removal efficiency of domestic MDG membrane can be improved. 목적 : 본 연구에서는 외산탈기막이 독점적으로 사용되는 초순수 공정에서 국산 Membrane degassing (MDG)공정을 개발하여 평가하였다. 초순수용 MDG 공정에 주로 사용되는 제품은 3M의 Liqui-celTM 제품이며, 국산MDG막은 화학공정 중 CO2 가스 공정에 사용되는 중공사막을 개선하여 모듈을 개발하였다. 초순수 공정의 최종 용존산소 관리 수준은 1 μg/L 이하이며, 국산막에 대한 용존산소 제거효율을 평가하여 외산막과 성능을 비교평가하였다. 방법 : 국산 MDG공정 개발에 대한 평가 방법으로 중공사막과 모듈에 대한 평가를 나누어 실시하였다. 우선, 중공사막의 평가를 위해 진공도, 질소가스 주입량 등의 운전조건을 변경하여 DO 제거율을 평가하였다. 외산 및 국산MDG막을 이용하여 질소농도와 진공도를 각각 2.5 ~ 5 L/min 및 30 ~ 150 mmHg로 변화시키며 평가하였다. 두 번째로 모듈에 대한 평가는 유기물 용출도를 평가하였으며, 또한 인입농도, 진공도, 질소가스량, 공급압력 등 4가지운전인자에 따른 용존산소 제거효율에 대해 평가하였다. 결과 및 토의 : 첫 번째로 국내 MDG 중공사막의 평가결과 진공도와 질소가스량의 조건에 따라 Liqui-celTM 막의경우 용존산소가 3.8 ~ 4.9 mg/L이며, 국내 중공사막의 경우 3.4 ~ 4.8 mg/L이다. 중공사막의 평가결과 국내 중공사막의 제거효율이 더 좋았다. 이는 막의 기공과 균일도에 의해 효율차이가 발생한 것이다. 두 번째로 국산 MDG 모듈 적용 결과 인입 DO 농도가 10 μg/L 이하일 경우 생산수 DO가 0 μg/L 수준으로 3M막과 비교하여 차이가없었으나, 인입 DO 농도, 진공도, 질소가스, 공급압력을 변경한 결과 DO제거율이 61 ~ 65% 수준으로 낮아졌다. 막의 패킹효율, 막의 두께, 기공의 사이즈에 의해 효율차이가 발생한 것이다. 결론 : MDG 중공사막에 대한 평가에서는 국산막의 제거효율이 더 좋았으며, 모듈을 구성하여 평가하면 효율이 낮아짐을 알 수 있었으며, 이는 모듈 구성이 집약도와 막의 저항이 증가함으로 제거효율이 낮아진다. 이를 극복하기위해서는 막의 기공 크기를 감소시키고, 막의 두께를 감소시켜 용존산소 제거효율을 높여야 한다.

시브사이즈 Ni - Mo 강 분말의 사출성형에 관한 연구

권병수,유승철,문인형 대한금속재료학회 1991 대한금속재료학회 학술대회 개요집 Vol.1991 No.1